Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis: Bridging Rheumatology and Dermatology
Symposium Date: Friday, February 17, 2017This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, February 17, 2018
Note: Credit Is No Longer Available
 | Allan Gibofsky, MD, JD, MACR, FACP, FCLM Professor of Medicine Weill Cornell Medicine Attending Rheumatologist Co-Director, Clinic for Inflammatory Arthritis Hospital for Special Surgery New York, NY |
 | Leon H. Kircik, MD Associate Clinical Professor of Dermatology Ichan School of Medicine at Mount Sinai, New York, NY Associate Clinical Professor of Dermatology Indiana University Medical Center, Indianapolis, IN Medical Director Physicians Skin Care, PLLC, Louisville, KY DermResearch, PLLC, Louisville, KY |
With psoriatic arthritis (PsA), effective diagnosis and treatment present a challenge. While dermatologists are the front-line clinicians managing psoriasis, they do not routinely screen for PsA. The rheumatologists,who are best positioned to treat PsA,do not have access to the patients unless referred by the dermatologists.
Coordination of care has never been more important than in the prompt diagnosis and treatment of PsA. With the substantial health and economic burden that PsA imposes, it is important for rheumatologists and dermatologists to join forces in education and practice to apply most current recommendations for screening for early detection, referral, and treatment.
This CME Outfitters symposium features expert faculty involved in the coordination of care for patients with PsA. These engaging experts discuss how to help practicing clinicians recognize the early signs of PsA and implement early screening techniques, examine recommendations for treatment, and advise on how and when to collaborate between dermatology and rheumatology.
At the end of this CE activity, participants should be able to:
- Implement appropriate, guideline-directed screening approaches in patients with psoriasis to facilitate a prompt diagnosis of PsA.
- Describe current treatment recommendations and emergent therapies for PsA.
- Strategize ways that specialists in rheumatology and dermatology can work together to improve detection and treatment of PsA.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify appropriate, guideline-directed screening approaches in patients to facilitate a prompt diagnosis of PsA.
- Describe current treatment recommendations and emergent therapies for PsA.
- Identify strategies that specialists in rheumatology and dermatology can use to work together to improve detection and treatment of PsA.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Rheumatologists, dermatologists, physician assistants, pharmacists, nurses, and other healthcare professionals with an interest in psoriatic arthritis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC,designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.10CEUs) Universal Activity Number:
Enduring: 0376-0000-17-004-H01-P
Type: knowledge-based
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21208 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky has disclosed that he serves on the speakers bureau for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc. He is a consultant for AbbVie; Amgen Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; and Pfizer Inc. He is a shareholder of AbbVie Inc.; Amgen Inc.; and Pfizer Inc.
Dr. Kircik has disclosed that he receives research/grants from Acambis; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Astellas Pharma US, Inc.; Asubio Pharma Co., Ltd.; Berlex Laboratories (Bayer HealthCare Pharmaceuticals); Biolife; Biopelle, Inc.; Boehringer-Ingleheim; Breckinridge Pharmaceutical, Inc.: Celgene Corporation; Centocor, Inc.; Coherus Biosciences; CollaGenex Pharmaceuticals; CombiMatrix; Coria Laboratories; Dermavant Labs; Dermiria, Inc.; Dow Pharmaceuticals Sciences, Inc.; DUSA Pharmaceuticals, Inc.; Eli Lilly and Company; Exeltis USA, Inc.; Ferndale Laboratories, Inc.; Galderma Laboratories, LP; Genentech, Inc.; GlaxoSmithKline, PLC; Health Point, LTD; Idera; Intendis, Inc.; Johnson & Johnson; LEO Pharma, Inc.; L?Oreal; 3M; Maruho Co., Ltd.; Merck & Co., Inc.; Medicis Pharmaceutical Corp.; NanoBio Corporation; Novartis AG; Noven Pharmaceuticals Corp.; Obagi Medical Products, Inc.; Onset; OrthoNeutrogena; Promius Pharma, LLC; PharmaDerm; Pfizer Inc.; Quatrix; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Taro Pharmaceutical Industries, Ltd.; Tolerx, Inc.; UCB, Inc.; Valeant Pharmaceuticals Intl.; Warner-Chilcott; and XenoPort, Inc.
He serves on the speakers bureau for Abbott Laboratories; Allergan, Inc.; Amgen Inc.; Assos Pharmaceuticals; Astellas Pharma US, Inc.; Cipher Pharmaceuticals US LLC; Connectics Corporation; Dermik Laboratories; Embil Pharmaceuticals; Exeltis, USA, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Innocutis Medical, LLC; Innovail; Johnson & Johnson; LEO Pharma, Inc.; L?Oreal; 3M; Onset; OrthoNeutrogena; PediaPharma; PharmaDerm; Serono (Merck Serono International SA); SkinMedica, Inc.; Stiefel Laboratories, Inc.; Sun Pharma; Taro Pharmaceutical Industries Ltd.; Triax Pharmaceuticals; UCB, Inc.; Valeant Pharmaceuticals Intl.; and Warner-Chilcott.
He serves on the advisory board for Aclaris Therapeutics, Inc.; Allergan, Inc.; Almirall; Anacor Pharmaceuticals, Inc.; Biogen Idec; Colbar; Celgene Corporation; Cipher Pharmaceuticals US LLC; Connectics Corporation; EOS; Exeltis, USA, Inc.; Ferndale Laboratories, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Intendis, Inc.; Innocutis Medical, LLC; ISDIN; Johnson & Johnson, NanoBio Corporation; OrthoNeutrogena; Promius Pharma, LLC; Quinnova Pharmaceuticals; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Sun Pharma; Valeant Pharmaceuticals, Intl.; and Warner-Chilcott.
He serves as a consultant for Allergan, Inc.; Almirall; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Colbar; Cipher Pharmaceuticals US LLC; CollaGenex Pharmaceuticals; Connetics Corporation; Exeltis USA, Inc.; Galderma Laboratories, LP; Genentech, Inc.; Intendis, Inc.; ISDIN; Johnson & Johnson; Laboratory Skin Care Inc.; LEO Pharma, Inc.; Medical International Technologies; Merck & Co., Inc.; Merz, Inc.; Novartis AG; OrthoNeutrogena; Promius Pharma, LLC; PuraCap Pharmaceutical LLC; SkinMedica, Inc.; Stiefel Laboratories, Inc.; Taro Pharmaceutical Industries, Ltd.; UCB, Inc.; Valeant Pharmaceuticals Intl; and ZAGE.
Erica Perilstein, MD (peer reviewer) has no disclosures to report.
Naomi Wong, RMA (peer reviewer) has no disclosures to report.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-068-021717-45
